Abstract: Computer-implemented methods for generating neural networks, and methods for classifying physiological data and patients based on the generated networks, are provided. The methods comprise determining values of a plurality of hyperparameters based on one or more properties of the received input data, which may be physiological data. A neural network comprising a plurality of layers is generated based on the hyperparameters, and is trained using the input data. If a first predetermined condition is not met, the values of one or more of the hyperparameters are updated. The steps of generating and training a neural network are repeated until the first predetermined condition is met. When the first predetermined condition is met, one of the trained neural networks is selected and is output.

Abstract: The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.

Abstract: A method of increasing muscle mass and strength in mammals by orally administering a therapeutically effective amount of phosphatidic acid. The phosphatidic acid is preferably administered as a plurality of doses per day with at least one dose being administered during the anabolic window following exercise. Preferably, the method further includes the cotemporaneous administration of a therapeutically effective amount of creatine, optionally as phosphatidylcreatine. In addition or in the alternative, the method further includes the cotemporaneous administration of a therapeutically effective amount of leucine, optionally as phosphatidylleucine.

Abstract: A secondary window includes a first glazing, a film, and a first frame. The first glazing includes a glass substrate having a thickness, between a first glazing surface opposite a second glazing surface, less than 2.0 millimeters. The film is attached to the first glazing surface. The first glazing is secured in the first frame, which at least partially surrounds the glazing. A second secondary window includes a second glazing secured in a second frame, which at least partially surrounds the second glazing. The second glazing includes (a) a first pane having a first-pane thickness less than 2.0 millimeters and (b) a second pane having a second-pane thickness that exceeds the first-pane thickness.

Abstract: A method of increasing muscle mass and strength in mammals by orally administering a therapeutically effective amount of phosphatidic acid. The phosphatidic acid is preferably administered as a plurality of doses per day with at least one dose being administered during the anabolic window following exercise. Preferably, the method further includes the cotemporaneous administration of a therapeutically effective amount of creatine, optionally as phosphatidylcreatine. In addition or in the alternative, the method further includes the cotemporaneous administration of a therapeutically effective amount of leucine, optionally as phosphatidylleucine.

Abstract: Small molecule inhibitors of XBP1 splicing by IRE1? are provided, as well as methods for their use in treating or preventing cancer (e.g., endocrine resistant breast cancer), diabetes, and obesity.

Abstract: In an embodiment, an electronic component includes a power semiconductor device embedded in a dielectric core layer and at least one contact layer protruding from a first side face of the dielectric core layer. The contact layer includes an electrically insulating layer and at least one contact pad arranged on the electrically insulating layer. The at least one contact pad is electrically coupled with the power semiconductor device.

Abstract: A secondary window includes a first glazing, a film, and a first frame. The first glazing includes a glass substrate having a thickness, between a first glazing surface opposite a second glazing surface, less than 2.0 millimeters. The film is attached to the first glazing surface. The first glazing is secured in the first frame, which at least partially surrounds the glazing. A second secondary window includes a second glazing secured in a second frame, which at least partially surrounds the second glazing. The second glazing includes (a) a first pane having a first-pane thickness less than 2.0 millimeters and (b) a second pane having a second-pane thickness that exceeds the first-pane thickness.

Abstract: A method, system, and computer program product provides efficient matching of shipments with carriers and real time online tracking of shipments. The method includes receiving a carrier input that includes a desired end destination of an equipment of the carrier, and a processor locating at least one available shipment having one of (i) a shipment pick-up point within a pre-established, shipment pick-up zone and (ii) a shipment delivery point within an acceptable shipment drop-off zone of the desired end destination. The processor dynamically determines and maps an optimal route and generates and displays an available shipment (AV) user interface (UI), with a complete route for the equipment from a desired starting point to the desired end destination. The processor then calculates and provides, via the AV UI, an opportunity cost of the shipment, based in part on a total number of empty miles associated with the route.

Abstract: In an embodiment, a method includes inserting an electronic component including a power semiconductor device embedded in a dielectric core layer into a slot in a side face of a circuit board. The inserting the electronic component causes one or more electrically conductive contacts on one or more surfaces of the electronic component to electrically couple with one or more corresponding electrical contacts arranged on one or more surfaces of the slot.

Abstract: The invention is directed to a process that combines the solvent deasphalting with resin hydrotreatment so as to reduce the costs associated with performing each of the steps separately. The integrated process of the invention permits higher product yields coupled with lower energy and transportation costs.

Abstract: The invention relates to methods of inhibiting the growth or proliferation of a cell, the method comprising reducing the expression or activity of at least one gene in the cell selected from the group consisting of BLOC1S1, CDC2L1, CNOT1, DDX54, EIF3I, FANCG, FBP1, IER2, KIF1A, LCK, NR2F1, PNRC1, POLR2A, POLR2B, POLR2C, PRPF6, PSMB4, PSMC5, PSMD1, RPS2, SCNN1A, SF3A3, TAF2, TOB1 and TSC22D4.

Abstract: Compositions, devices, and methods of stabilizing Magneli phase materials are presented where the modified materials have a host phase and a locking phase in which locking compounds prevent rearrangement of a Magneli shear plane to a rutile structure and so prevent or reduce the oxidation of the Magneli phase material.

Abstract: A remotely deployable network of multi-rotor aircraft and landing stations enable widespread use of multi-rotor aircraft in varied environments and application scenarios. A multi-rotor aircraft having modular components to facilitate a range of applications performs remote operations. Landing stations provide a power source to remote aircraft and facilitate semi-autonomous landing. A computing device facilitates use interaction with a network of multi-rotor aircraft and landing stations that together form a network for transmitting data concerning individual and regional aircraft operations.

Abstract: Small molecule inhibitors of XBP1 splicing by IRE1? are provided, as well as methods for their use in treating or preventing cancer (e.g., endocrine resistant breast cancer), diabetes, and obesity.

Abstract: The invention relates to cancer, and more specifically to breast cancer, and particularly to estrogen receptor positive breast cancer that is resistant to endocrine therapy. The invention provides methods for selecting subgroups of subjects for treatment, and methods of treatment of a subgroup of subjects.

Abstract: A method, system, and computer program product provides efficient matching of shipments with carriers and real time online tracking of shipments. The method includes receiving a carrier input that includes a desired end destination of an equipment of the carrier, and a processor locating at least one available shipment having one of (i) a shipment pick-up point within a pre-established, shipment pick-up zone and (ii) a shipment delivery point within an acceptable shipment drop-off zone of the desired end destination. The processor dynamically determines and maps an optimal route and generates and displays an available shipment (AV) user interface (UI), with a complete route for the equipment from a desired starting point to the desired end destination. The processor then calculates and provides, via the AV UI, an opportunity cost of the shipment, based in part on a total number of empty miles associated with the route.

Abstract: The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.

Abstract: Compositions, devices, and methods of stabilizing Magneli phase materials are presented where the modified materials have a host phase and a locking phase in which locking compounds prevent rearrangement of a Magneli shear plane to a rutile structure and so prevent or reduce the oxidation of the Magneli phase material.

Abstract: Small molecule inhibitors of XBP1 splicing by IRE1 are provided, as well as methods for their use in treating or preventing cancer (e.g., endocrine resistant breast cancer), diabetes, and obesity.